Shares of Prothena Corp. Plc /zigman2/quotes/204713496/composite PRTA -1.43% were up 1.3% in premarket trading on Monday after the company announced a deal to sell its ATTR amyloidosis portfolio to Novo Nordisk /zigman2/quotes/207193277/delayed DK:NOVO.B +0.42% in a $100 million deal that is worth up to $1.2 billion, based on milestones. ATTR amyloidosis is a rare disease that can cause a buildup of amyloid deposits in the body. One of the therapies in the portfolio is an experimental monoclonal antibody drug that has completed a Phase 1, open-label clinical trial. Prothena's stock has soared 393.2% so far this year, while the S&P 500 /zigman2/quotes/210599714/realtime SPX -0.65% is up 16.3%.
An earlier version incorrectly described the portfolio being sold to Novo Nordisk. It has been corrected.